Pharmacogenomics in Drug Discovery and Development/Edited by Qing Yan, PharmTao
Santa Clara, CA, USA 2008 Humana Press
Comentario:
Contents:
ix
Chapter 1 The Integration of Personalized and Systems Medicine:
Bioinformatics Support for Pharmacogenomics
and Drug Discovery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Qing Yan
Chapter 2 Applications of Microarrays and Biochips
in Pharmacogenomics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Gary Hardiman
Chapter 3 Confounding in Genetic Association Studies
and Its Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Donglei Hu and Elad Ziv
Chapter 4 Pharmacogenetics of Membrane Transporters: A Review
of Current Approaches . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Tristan M. Sissung, Erin R. Gardner, Rui Gao,
and William D. Figg
Chapter 5 Pharmacogenomics of Drug-Metabolizing
Enzymes and Drug Transporters in Chemotherapy . . . . . . . . 63
Tessa M. Bosch
Chapter 6 Pharmacogenomics of G Protein-Coupled Receptor
Signaling: Insights from Health and Disease . . . . . . . . . . . . . . 77
Miles D. Thompson, David E. C. Cole, and Pedro A. Jose
Chapter 7 G Protein-Coupled Receptors Disrupted in Human
Genetic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Miles D. Thompson, Maire E. Percy, W. McIntyre Burnham,
and David E. C. Cole
Chapter 8 G Protein-Coupled Receptor Pharmacogenetics . . . . . . . . . . 139
Miles D. Thompson, Katherine A. Siminoivitch,
and David E. C. Cole
Chapter 9 Epigenetic Alterations of the Dopaminergic System
in Major Psychiatric Disorders . . . . . . . . . . . . . . . . . . . . . . . . 187
Hamid Mostafavi Abdolmaleky, Cassandra L. Smith,
Jin-Rong Zhou, and Sam Thiagalingam
Chapter 10 Pharmacogenomics in Alzheimer’s Disease . . . . . . . . . . . . . . 213
Ramón Cacabelos
Chapter 11 Pharmacogenetics of Asthma. . . . . . . . . . . . . . . . . . . . . . . . . . 359
Gregory A. Hawkins and Stephen P. Peters
Chapter 12 From SNPs to Functional Studies in Cardiovascular
Pharmacogenomics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379
Sharon Cresci
Chapter 13 Pharmacogenomics in Gastrointestinal Disorders . . . . . . . . 395
Michael Camilleri and Yuri A. Saito
Chapter 14 Pharmacogenomics in Rheumatoid Arthritis . . . . . . . . . . . . 413
Prabha Ranganathan
Chapter 15 Cancer Pharmacogenetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437
Sharon Marsh
Chapter 16 Pharmacogenomics in the Preclinical Development
of Vaccines: Evaluation of Efficacy and Systemic
Toxicity in the Mouse Using Array Technology. . . . . . . . . . . . 447
Karin J. Regnström
Chapter 17 Pharmacogenomics in the Evaluation of Efficacy
and Adverse Events During Clinical Development
of Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 469
Lennart J. Nilsson and Karin J. Regnström
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 481
Publicar un comentario